Key result
Trimetazidine improves GLS by ~28% versus control in stable angina patients.
Why the study?
It was unknown whether short-term trimetazidine therapy could improve CMR-assessed LV GLS in patients with stable angina, prior MI, reduced LVEF, and viable myocardium.
Does trimetazidine improve left ventricular global longitudinal strain assessed by CMR in patients with stable angina, prior MI, and impaired LVEF?
Population
52 patients with stable angina, prior MI, impaired LVEF, and viable myocardium in Azerbaijan
Comparison
TMZ 80 mg plus GDMT vs GDMT alone
Design
Prospective randomized trial
Follow-up
8 weeks
Authors
Loading...
Trimetazidine may improve subclinical LV function in stable angina; challenges prior evidence against benefit and supports GLS over LVEF.
RCT (n=52)
randomized
Does trimetazidine improve left ventricular global longitudinal strain assessed by CMR in patients with stable angina, prior MI, and impaired LVEF?
Absolute Event Rate: -12.7% vs -10.3%
p-value: p=0.00
Short-term trimetazidine therapy significantly improves left ventricular global longitudinal strain assessed by CMR in patients with stable angina and LV dysfunction, even before changes in LVEF are detectable.
Rustamova et al. (2026) conducted an RCT in Stable angina with left ventricular dysfunction (n=52). Trimetazidine vs. Guideline-directed medical therapy alone was evaluated on Change in left ventricular global longitudinal strain (GLS) assessed by CMR (p=0.00). Trimetazidine 80 mg added to GDMT significantly improved CMR-based global longitudinal strain from -9.9% to -12.7% (p=0.00) at 8 weeks in patients with stable angina and LV dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: